Boston Scientific still sells devices used in recurring cardiovascular and minimally invasive procedures, with valuable physician training relationships, regulatory approvals and product franchises. Interventional Cardiology grew 19% in Q3 and Neuromodulation grew 13%, providing real offsets to weakness elsewhere.

The former double-digit growth case has weakened. Q3 organic revenue rose just 1.5%, EP sales fell 5% globally and WATCHMAN fell 6%. Management sees 2027 as a difficult organic growth year even after the cybersecurity disruption fades. The company needs to regain U.S. EP procedure share, improve WATCHMAN referrals, restore margins and bring new products to market before a return to premium earnings growth can be assumed.

The approved base case now assumes $3.85 of sustainable 2029 EPS and a 18× exit P/E, rather than the prior $4.10 and 20×. This recognizes potential recovery in 2028–2029 without assuming a quick rebound.

What the Market May Be Mispricing

Debate	Research judgment
Cyber disruption	Q3 estimated $150M lost sales and $0.07 adjusted EPS impact should fade, but that cannot explain persistent EP share loss
EP competition	The PFA market remains attractive, yet Medtronic, Abbott and Johnson & Johnson compete for physician workflows and BSX is losing U.S. share
WATCHMAN demand	Standalone referral declines and competition create a separate structural risk; SIMPLAAFY is encouraging, not a volume forecast
Penumbra and capital allocation	Acquired growth can diversify the company but must be evaluated after financing costs and dilution
Launch timetable	2D ICE planned H2 2027; FARAWAVE Ultra early 2028; FARAFLEX 2029. These timing assumptions carry execution risk

Boston Scientific sells devices for minimally invasive procedures. Cardiovascular covers electrophysiology, cardiac rhythm management, WATCHMAN left atrial appendage closure, interventional cardiology and vascular therapy; MedSurg includes Endoscopy, Urology and Neuromodulation. Hospitals, physicians and purchasing networks buy devices based on procedure outcomes, training, workflow, evidence and reimbursement. Consumable procedure demand is recurring, but platform innovation can change physician choices.

Business	Q3 2026 revenue	Organic growth	Business read-through
Endoscopy	$741M	−0.6%	China pricing and supply effects
Urology	$661M	−3.1%	Commercial execution and procedure challenges
Neuromodulation	$331M	+13.0%	Strong growth offset
MedSurg total	$1.733B	+0.7%	Diversified but slower
Cardiovascular total	$3.406B	+1.9%	Interventional Cardiology strength offset by EP/WATCHMAN

Business Takeaway

Boston Scientific's scale and physician relationships make its products durable, but the value of the franchise depends on retaining procedure share and healthy gross profit in the fastest-changing categories.

Aging populations, minimally invasive treatment and better diagnosis expand procedures. Electrophysiology and left-atrial-appendage closure also attract well-financed competitors. Reimbursement changes and clinical evidence can alter adoption quickly. Addressable patient counts must be reduced for eligibility, access and physician willingness to change practice.

Market-Share Analysis

Comparable same-definition share data for the subject and its principal rivals were not established. TAM estimates and company-specific volume measures are not treated as directly comparable market shares. The positioning analysis below is more reliable than a table of unmatched percentages.

Competitive Scale / Position

Company / Platform	Primary Position	Relative Scale	Growth Direction	Investment Relevance
Medtronic (MDT)	Direct segments: electrophysiology, cardiac rhythm, neuromodulation	Product scope; no matched operating-scale series	Competes in overlapping procedures	Customer choice in the stated segment only
Abbott (ABT)	Direct segments: electrophysiology and structural heart	Product scope; no matched operating-scale series	Competes for physician and hospital adoption	Customer choice in the stated segment only
Johnson & Johnson — Biosense Webster	Direct segment: electrophysiology mapping and ablation	Product scope; no matched operating-scale series	EP procedure choice determines overlap	Customer choice in the stated segment only

Industry Takeaway

Addressable patient counts must be reduced for eligibility, access and physician willingness to change practice. The base case requires evidence of profitable adoption within that market.

Competitive Landscape

The comparison is by procedure and device category. Orthopedic exposure alone does not make Stryker a broad Boston Scientific peer.

Competitor	Market Share	Positioning	Advantages vs. Company	Disadvantages vs. Company	Current Direction
Medtronic (MDT)	No consistent comparable series	Direct segments: electrophysiology, cardiac rhythm, neuromodulation	Broad clinical distribution and installed devices	Product-level outcomes matter more than group scale	Competes in overlapping procedures
Abbott (ABT)	No consistent comparable series	Direct segments: electrophysiology and structural heart	Competing mapping, ablation and Amulet offerings	Diagnostics and nutrition are outside the BSX comparison	Competes for physician and hospital adoption
Johnson & Johnson — Biosense Webster	No consistent comparable series	Direct segment: electrophysiology mapping and ablation	Established EP mapping/workflow ecosystem	Does not replicate every BSX cardiovascular franchise	EP procedure choice determines overlap

Moat Assessment

Regulatory approvals, clinical data, physician familiarity and broad distribution form a strong moat. Competitive product launches can still shift share. The latest slowdown argues for a stable-to-challenged near-term moat assessment in affected franchises rather than extrapolating historical share gains indefinitely.

Moat direction: Weakening — an analytical judgment about product and distribution economics, not a measured market-share claim.

Competitive Takeaway

Regulatory approvals, clinical data, physician familiarity and broad distribution form a strong moat. The direct rivals determine commercial pressure; diversified or sector anchors provide valuation context and are not substitutes for direct competition.

Historical Financials

Financial reporting periods follow the issuer's fiscal year: completed FY rows plus standalone current-year quarters and cumulative H1/9M for FY2026. Revenue, FCF and SBC are flows; cash is a period-end balance. FCF = operating cash flow minus property/equipment capex from SEC company facts; quarterly FCF after Q1 and any quarterly SBC derived from YTD are visibly marked. Missing values are N/D, not zero. Unit: USD millions. Data extracted from SEC-tagged filings as of 2026-11-07. Company-specific FCF definitions and acquisition effects may require further reconciliation.

Period	Revenue	Growth	Gross Margin	Operating Margin	FCF	FCF Margin	SBC	Diluted Shares	Cash	Debt
FY2023	14,240	12.29%	69.16%	16.97%	1,792	12.58%	233	1,464	865	9,568
FY2024	16,747	17.61%	68.41%	17.93%	2,645	15.79%	266	1,486	414	11,228
FY2025	20,074	19.87%	68.78%	19.78%	3,658	18.22%	299	1,495	1,965	11,972
Q1 FY2026	$5,203	N/D	69.5%	21.2%	$171 (derived: CFO - capex)	3.3%	$83	1,495	$1,453	N/D
Q2 FY2026	$5,442	N/D	70.7%	21.6%	$1,279 (derived: current YTD - prior YTD)	23.5%	$87 (derived: current YTD - prior YTD)	1,474.8	$539	N/D
H1 FY2026	$10,646	N/D	70.1%	21.4%	$1,450 (derived: CFO - capex)	13.6%	$170	1,484.9	$539	N/D
Q3 FY2026	$5,138	N/D	66.7%	16.1%	$868 (derived: current YTD - prior YTD)	16.9%	$72 (derived: current YTD - prior YTD)	1,452	$609	N/D
9M FY2026	$15,784	N/D	69.0%	19.7%	$2,318 (derived: CFO - capex)	14.7%	$242	1,473.9	$609	N/D

Supplemental historical reporting context (retained)

Supplemental historical reporting context (retained)

Supplemental historical reporting context (retained)

Quarterly FCF derivation: Q1 = $348M CFO − $177M capex = $171M; Q2 = ($1,822M − $348M) CFO − ($372M − $177M) capex = $1,279M; Q3 = ($2,870M − $1,822M) CFO − ($552M − $372M) capex = $868M. Quarterly SBC: Q1 $83M, Q2 $170M − $83M = $87M, Q3 $242M − $170M = $72M. Corresponding Q3 SBC/FCF is approximately 8.3% and 9M SBC/FCF approximately 10.4%; FolioFacts derives ratios from matching periods rather than accepting a separate stored field.

Financial Takeaways

Q3 revenue was $5.138B, up 1.5%; GAAP diluted EPS $0.40 versus $0.51 and adjusted EPS $0.73 versus $0.75, below management's $0.80–$0.82 guidance. Adjusted gross margin fell to 68.0% from 71.0%; adjusted operating margin fell to 26.5% from 28.0%. Cyber costs caused material factory absorption and shipping headwinds, but worsening EP mix, WATCHMAN demand and China pricing create structural risks.

The company estimates the August cyber incident reduced Q3 revenue growth approximately 300 basis points and adjusted EPS $0.07, with another 200–300 basis points of Q4 revenue pressure as restocking unwinds. Management cut FY2026 organic growth guidance to ~3.75% and adjusted EPS to $3.16–$3.18; Q4 organic revenue is expected to decline 1–3%. Free cash flow remains positive, but 9M operating cash flow declined from $3.170B to $2.870B. September 30 cash totaled $609M against $11.953B debt. First-year Penumbra financing and share dilution remain uncertain.

Financial direction: Deteriorating in organic growth and margins; strong cash conversion persists.

Current Valuation

Metric	Value
Price Snapshot	$42.75 — November 6, 2026 regular-session close
Shares Outstanding	~1.449B, October 29 2026 share count
Market Capitalization	$61.96B
Cash / Total Debt	$0.609B / $11.953B as of September 30, 2026
Enterprise Value	$73.31B
Trailing P/E	18.05×
Provider Forward P/E	13.87×
EV / Sales	~3.48× on latest-12-month revenue (not a cash-flow chart series)

Comparable Company Analysis

Company	Relevance	Public / Private	Forward P/E	EV / Sales	Growth / Margin / Risk Context
BSX — Boston Scientific	Subject company	Public	13.87×	3.48×	Cash-generative, challenged EP and WATCHMAN organic growth
MDT — Medtronic	Device competitor in specific cardiovascular/neuromodulation procedures; diversified valuation anchor	Public	16.95×	3.83×	Broader business mix; not a direct group-wide peer
ABT — Abbott	EP and LAAC segments; diversified valuation anchor	Public	18.84×	N/D	Diagnostics/diabetes complicate consolidated comparison
JNJ — Biosense Webster	Direct EP ablation and mapping product competitor	Listed parent	N/D	N/D	No matched product-level multiple; not a comparable consolidated P/E

Comparable takeaway: Same-provider November 6 quote convention for listed valuation anchors. The 18× BSX base exit multiple is an independent judgment about future normalized earnings rather than a mechanical peer average.

Valuation Scenarios

Scenario	Key Assumptions	Fair Value	Probability	Probability Rationale	Return From Price Snapshot
Bear	Sustainable 2029 EPS $2.75; exit P/E 13×; 12% discount over three years; prolonged franchise loss	$25.45	35%	Higher probability of persistent competition, financing drag and slow growth	−40.5%
Base	Sustainable 2029 EPS $3.85; exit P/E 18×; 12% discount over three years; weak 2027 then recovery	$49.33	50%	Diversified cash flows and eventual pipeline commercialization	+15.4%
Bull	Sustainable 2029 EPS $4.75; exit P/E 23×; 12% discount over three years; strong pipeline and deal execution	$77.76	15%	Multiple product recoveries and improved margins required	+81.9%
Probability-Weighted	35% × $25.45 + 50% × $49.33 + 15% × $77.76	$45.23	100%	Independent scenario weights	+5.8%

Valuation Takeaway

• Primary valuation method: Present value of sustainable 2029 EPS times exit P/E, discounted at 12% over three years. The EPS estimates are after recurring compensation, potential Penumbra financing and share dilution, not a naive extrapolation of adjusted EPS.
• Valuation refresh date / changes vs. previous: 2026-11-07. Bear/Base/Bull changed from $27.90/$58.37/$88.97 to $25.45/$49.33/$77.76; probabilities from 25/50/25 to 35/50/15, yielding P/W $45.23 versus $58.40 (−22.5%). Base sustainable EPS decreased from $4.10 to $3.85 and exit P/E from 20× to 18×; bear and bull multiples reduced to 13× and 23×. The 12% discount rate and three-year horizon are retained after reassessment to preserve consistent treatment of uncertain 2029 earnings. These are analyst assumptions, not issuer guidance or consensus.
• Cross-check methods: The issuer's 2026 adjusted EPS midpoint $3.17, positive cash flow, current quoted forward P/E 13.87× and similar-date MDT/ABT valuations. The base $3.85 sustainable EPS requires approximately 10% annual EPS growth in 2028 and 2029 after a difficult 2027.
• Key valuation dependencies: U.S. EP share stabilization, WATCHMAN referrals, China pricing, margins after cyber, the product timetable, Penumbra financing and dilution.
• Valuation confidence / Risk Level: 45/100 / Medium-High (previously 55/100).
• Margin-of-safety conclusion: Hold at the November 6 $42.75 reference price, with only +5.8% probability-weighted upside and −40.5% bear downside. Indicative research-date zone boundaries are Strong Buy ≤ $27.99, Buy up to $36.19, and Avoid Chasing above $50.26. FolioFacts alone calculates live zones, Opportunity Score and rank.

Management's past product commercialization is valuable, but repeated revisions to EP/WATCHMAN forecasts, a cybersecurity disruption and launch delays reduce near-term execution confidence. It plans more than $500M restructuring savings over three years, with more than half the savings on an exit-rate basis by the end of 2027; savings cannot alone recapture share. Penumbra's closing is expected in early 2027 after regulatory review. Previously guided $0.06–$0.08 first-year adjusted EPS dilution may rise with financing costs. The company completed an accelerated $2B repurchase, but new deal dilution and debt must be considered on a per-share basis.

Management Takeaway

Look for evidence that updated forecasting, product development, supply resilience and acquisition financing translate into stabilized U.S. EP sales, WATCHMAN referrals, improved margins and sustained per-share cash earnings.

Analyzed call: Q3 2026 full material Q&A · Research snapshot: 2026-11-07

Full material Q3 2026 earnings-call Q&A, October 28. Questions and responses are original paraphrases rather than a transcript reproduction. Previous Q2 coverage remains in Git history.

Analyst / Firm	Core Question	Management Response	Research Read-Through
Robbie Marcus / JPMorgan	How much of the weak quarter and the difficult 2027 outlook is attributable to the cybersecurity disruption, and how much reflects underlying market weakness?	CFO Jon Monson estimated a $150 million sales hit and $0.07 EPS hit in Q3. Customer restocking after systems returned should produce another two to three points of revenue pressure and $0.04–$0.05 of EPS pressure in Q4. CEO Mike Mahoney said the larger 2027 issue is continued WATCHMAN market weakness and EP share erosion, even if the cyber effects fade.	The outage does not explain the whole reduction in forward earnings power.
Larry Biegelsen / Wells Fargo	Why should sales and earnings accelerate in 2028 despite delayed FARAFLEX development and possible new PFA competition?	Mahoney expects interventional and vascular businesses, together with Penumbra, to grow strongly, with MedSurg closer to mid-single-digit market growth. A new cardiac-rhythm platform, additional EP imaging and ablation launches, and possible WATCHMAN label developments are expected to improve the slower franchises. FARAFLEX remains a 2029 opportunity.	The anticipated 2028 recovery depends on multiple introductions and several markets, not one guaranteed launch.
Joanne Wuensch / Citi	What internal changes can bridge earnings to 2028, and what remains before the Penumbra deal can close?	Management described staff and cost restructuring, simpler reporting lines, supply-chain work and back-office changes. It expects more than $500 million of savings over three years and more than half of the savings by the end of 2027 on an exit-rate basis. It also said regulatory discussion had extended Penumbra's anticipated closing into early 2027, without a definitive date.	Cost savings may protect earnings, but acquisition timing and underlying growth remain separate risks.
Rick Wise / Stifel	Why should MedSurg grow only in the mid-single digits, rather than return to its former 7%–8% growth rate?	Neuromodulation remains strong. Endoscopy faces Chinese pricing cuts until it laps them late in 2027. Urology has suffered from weak stone-product performance and commercial turnover following the Axonics integration. Recent product clearances and added field staff are expected to improve Urology in 2027, while broader MedSurg acceleration is more likely in 2028.	Even outside EP and WATCHMAN, there are execution issues to resolve.
Travis Steed / Bank of America	Do the repeated product delays signal a deeper problem with the pipeline, and what has management changed in its forecasting process?	The CFO acknowledged that management had struggled to forecast the changing EP and WATCHMAN business cycle and described expanded scenario modeling, outside data and process changes. Mahoney acknowledged delays of roughly six months on some large platforms, citing development and regulatory complexity and a reorganization intended to improve launch discipline.	Better forecasts must be demonstrated through results; a stronger process is not yet evidence of a better outcome.
Josh Jennings / TD Cowen	Is Boston Scientific's estimated 7% weighted-average market growth rate still credible, and how does management view the U.S. EP market?	Mahoney said the overall market-growth estimate remains around 7%, potentially reaching 7%–8% as new categories and Penumbra are added. He continues to see a healthy EP market even while Boston Scientific loses share. Management expects the company to grow below its weighted market rate in 2027 and move back toward it in 2028.	End-market demand and Boston Scientific's competitive performance must be modeled separately.
Marie Thibault / BTIG	Why wouldn't restructuring produce adjusted EPS growth in 2027, even if revenue is weak?	Monson said product mix is the biggest constraint. Lower EP and WATCHMAN sales, combined with more intense pricing pressure in China, are expected to weigh on gross margin. Continued investment in quality and development offsets part of the savings. The company expects EPS growth to remain difficult without a revenue recovery.	Savings are an offset to deterioration, not an independent basis for higher earnings.
Pito Chickering / Deutsche Bank	Why is THRIVE running behind schedule, and why is VITALYST focusing initially on cardiogenic shock rather than high-risk PCI?	Chief Medical Officer Ken Stein said THRIVE enrollment has been slower than hoped during integration of the SoniVie team. For VITALYST, management wants to first pursue cardiogenic shock, where it believes the clinical need and potential benefit are compelling, rather than lead with the more debated high-risk PCI application.	The development strategy may be sensible, but launch timing and clinical success remain uncertain.
Matthew O'Brien / Piper Sandler	Are the FARAWAVE Ultra and FARAFLEX delays due to technical problems, clinical enrollment or manufacturing, and what can be said about the Penumbra delay?	Joe Fitzgerald attributed Ultra's roughly one-quarter slip primarily to design verification and validation across hardware, software and catheter components, rather than a required clinical trial. FARAFLEX has faced regulatory study approvals and practical startup challenges; management expects enrollment to ramp. Mahoney did not add details beyond Penumbra's expected early-2027 close.	These are different bottlenecks, but together they push the commercial recovery further into the future.
Matt Taylor / Jefferies	How has Penumbra's expected growth and its first-year EPS dilution changed since the deal was announced?	Monson said Penumbra remains an attractive growth addition, but the original $0.06–$0.08 estimated first-year adjusted EPS dilution used earlier financing assumptions. Higher interest rates may increase that dilution, and management will give a fuller update after closing.	Acquisition-driven growth needs to be judged after financing costs and dilution, not simply by added revenue.

Analyst-Q&A Takeaway

The Q3 call made clear that the cyber incident is not the whole problem. Analysts pressed management on EP and WATCHMAN competition, the 2027 trough, restructuring and Penumbra deal dilution, clinical program delays and recovery timing. Management anticipates more improvement in 2028–2029 but acknowledges weak 2027 organic growth and several milestones still ahead. This shifts valuation probability toward the bear case and lowers the sustainable base-case EPS and exit multiple.

Source	Type	Date / Period	What It Supports
Boston Scientific Q3 2026 earnings release	Company IR	2026-10-28 / Q3 2026	Sales, margins, EPS, organic growth, guidance and franchise results
Q3 2026 investor highlights	Company presentation	Q3 2026	Segment metrics, clinical and commercial milestones
BSX Q3 2026 SEC Form 10-Q	SEC filing	Filed 2026-11-02	Financial statements, cash, debt, SBC, shares, cyber risk
BSX Q2 2026 SEC Form 10-Q	SEC filing	Q2/H1 2026	Interim cumulative cash flow, Q2 diluted shares and SBC
BSX Q1 2026 SEC Form 10-Q	SEC filing	Q1 2026	Quarter CFO, capex, SBC, revenue and balance sheet
Q3 2026 earnings-call transcript	Transcript	2026-10-28	Full material Q&A and forward-looking management commentary
SIMPLAAFY WATCHMAN trial	Clinical trial, JAMA	2026-11-02	Post-implant medication trial outcomes and limitations
BSX historical annual financials	Standardized financial data	FY2023–FY2025	Annual revenue, margins, share count
BSX annual cash flows	Standardized financial data	FY2023–FY2025	Annual operating FCF and SBC
BSX November 6 close	Market data	2026-11-06	Dated share price
BSX valuation statistics	Market data	2026-11-06 quote, checked 2026-11-07	Market cap, EV, P/E and EV/Sales
MDT valuation statistics	Comparable market data	2026-11-06 quote	Matched provider/price-date peer multiple
ABT valuation statistics	Comparable market data	2026-11-06 quote	Matched provider/price-date peer multiple
Boston Scientific announces results for second quarter 2026 - Jul 29, 2026	Company IR / earnings filing	Q2 2026	Latest operating results, guidance, products and financial supplement
BSX complete earnings-call transcript	Transcript	Q2 2026	Prepared remarks and all material Q&A exchanges
BSX regular-session historical price	Market data	2026-10-20 close	Common price used in returns, scores and zones
BSX historical income statement	Standardized financial statements	Latest reported period and two preceding fiscal years	Historical income statement; source-native currency and definitions
BSX historical balance sheet	Standardized financial statements	Latest reported period and two preceding fiscal years	Historical balance sheet; source-native currency and definitions
BSX historical cash flows	Standardized financial statements	Latest reported period and two preceding fiscal years	Historical cash flows; source-native currency and definitions
Medtronic plc statistics	Comparable-company market data	2026-10-20 regular close	Peer multiples and financial context; public quote basis
Abbott statistics	Comparable-company market data	2026-10-20 regular close	Peer multiples and financial context; public quote basis
SEC XBRL company facts — BSX	Regulatory filing (as tagged)	FY2026, through 2026-09-30	Current-year standalone-quarter and year-to-date source facts for FCF, SBC, revenue and other reported metrics

Research context

• Company: Boston Scientific Corporation
• Ticker: BSX
• Exchange: NYSE
• Sector / Industry: Health Care / medical devices
• Template version: 2.7
• Research date: 2026-11-07
• Valuation / score price snapshot: $42.75 — 2026-11-06 regular-session close, America/New_York
• Valuation refresh date: 2026-11-07
• Tracking tier: Primary Watchlist
• Owned: Yes
• Primary operating period reviewed: Q3 2026
• Historical period reviewed: FY2023–FY2025 and Q1–Q3/9M FY2026
• Latest investor presentation reviewed: Q3 2026 financial and operational highlights
• Latest earnings call reviewed: Q3 2026 full material Q&A
• Latest post-earnings management commentary reviewed: SIMPLAAFY trial publication, November 2, 2026

The share price is a dated research reference, not a live portfolio quote. FolioFacts owns live prices, opportunity scores, zones and rankings.

BSX — Boston Scientific Corporation

Company & Research Metadata

• Company: Boston Scientific Corporation
• Ticker: BSX
• Exchange: NYSE
• Sector / Industry: Health Care / medical devices
• Template version: 2.7
• Research date: 2026-11-07
• Valuation / score price snapshot: $42.75 — 2026-11-06 regular-session close, America/New_York
• Valuation refresh date: 2026-11-07
• Tracking tier: Primary Watchlist
• Owned: Yes
• Primary operating period reviewed: Q3 2026
• Historical period reviewed: FY2023–FY2025 and Q1–Q3/9M FY2026
• Latest investor presentation reviewed: Q3 2026 financial and operational highlights
• Latest earnings call reviewed: Q3 2026 full material Q&A
• Latest post-earnings management commentary reviewed: SIMPLAAFY trial publication, November 2, 2026

The share price is a dated research reference, not a live portfolio quote. FolioFacts owns live prices, opportunity scores, zones and rankings.

What's Changed Since Previous Review

Current Review: 2026-11-07
Previous Review: 2026-10-28 competitor-Q&A audit; 2026-10-21 substantive model
Update Trigger: Q3 2026 earnings, guidance and approved valuation refresh

Area	Previous View	Current View	Investment Impact
Growth	Q2 organic +7%, FY2026 5–6% guidance	Q3 +1.5%, FY2026 ~3.75%, Q4 −3% to −1%	Lower near-term earnings power
EP and WATCHMAN	Slowing but recovery plausible	EP −5%, U.S. EP −8%; WATCHMAN −6%; management anticipates difficult 2027	Lower sustainable EPS and multiple
Cybersecurity	No modeled global disruption	~300bp Q3 organic revenue hit, ~$0.07 Q3 adjusted EPS hit; Q4 order normalization	Temporary effect distinct from structural competition
Financial quality	Strong margins, acquisition leverage	Q3 adjusted gross margin down to 68%, potential Penumbra finance dilution	Less margin visibility
Clinical evidence	WATCHMAN recovery uncertain	SIMPLAAFY monotherapy results supportive but adoption unknown	Potential catalyst, not immediate forecast revenue
Fair values	$27.90 / $58.37 / $88.97; P/W $58.40; 25/50/25	$25.45 / $49.33 / $77.76; P/W $45.23; 35/50/15	P/W fair value −22.5% from fundamentals
Quality / confidence	80.1/A; confidence 55	74.4/B; confidence 45	Weaker moat, growth and execution certainty

Thesis: Weakened. The share-price change is separate from the fundamental estimate reduction. The operating case is a multiyear recovery requiring evidence of EP share stabilization, WATCHMAN referral improvement and disciplined acquisition financing.

Investment Snapshot

Metric	Current View
Price Snapshot	$42.75, November 6, 2026 regular-session close
Research Rating	Hold (dated fundamental judgment)
Bear / Base / Bull Fair Value	$25.45 / $49.33 / $77.76
Scenario Probabilities	35% / 50% / 15%
Probability-Weighted Fair Value	$45.23
Research-date P/W Return / Bear Return	+5.8% / −40.5%
Quality Score / Tier	74.4 / B
Risk Level	Medium-High
Valuation Confidence	45 of 100
Tracking / Ownership	Primary Watchlist / Owned

Decision rationale: The cyber outage explains some of the quarterly shortfall, but EP market-share erosion, WATCHMAN referral weakness and delayed launches constrain 2027 organic growth. Just 5.8% modeled expected return at $42.75 does not warrant a new Buy with material downside risk. FolioFacts determines live price-derived opportunity classifications.

Investment Thesis

Boston Scientific still sells devices used in recurring cardiovascular and minimally invasive procedures, with valuable physician training relationships, regulatory approvals and product franchises. Interventional Cardiology grew 19% in Q3 and Neuromodulation grew 13%, providing real offsets to weakness elsewhere.

The former double-digit growth case has weakened. Q3 organic revenue rose just 1.5%, EP sales fell 5% globally and WATCHMAN fell 6%. Management sees 2027 as a difficult organic growth year even after the cybersecurity disruption fades. The company needs to regain U.S. EP procedure share, improve WATCHMAN referrals, restore margins and bring new products to market before a return to premium earnings growth can be assumed.

The approved base case now assumes $3.85 of sustainable 2029 EPS and a 18× exit P/E, rather than the prior $4.10 and 20×. This recognizes potential recovery in 2028–2029 without assuming a quick rebound.

What the Market May Be Mispricing

Debate	Research judgment
Cyber disruption	Q3 estimated $150M lost sales and $0.07 adjusted EPS impact should fade, but that cannot explain persistent EP share loss
EP competition	The PFA market remains attractive, yet Medtronic, Abbott and Johnson & Johnson compete for physician workflows and BSX is losing U.S. share
WATCHMAN demand	Standalone referral declines and competition create a separate structural risk; SIMPLAAFY is encouraging, not a volume forecast
Penumbra and capital allocation	Acquired growth can diversify the company but must be evaluated after financing costs and dilution
Launch timetable	2D ICE planned H2 2027; FARAWAVE Ultra early 2028; FARAFLEX 2029. These timing assumptions carry execution risk

Business Overview

Boston Scientific sells devices for minimally invasive procedures. Cardiovascular covers electrophysiology, cardiac rhythm management, WATCHMAN left atrial appendage closure, interventional cardiology and vascular therapy; MedSurg includes Endoscopy, Urology and Neuromodulation. Hospitals, physicians and purchasing networks buy devices based on procedure outcomes, training, workflow, evidence and reimbursement. Consumable procedure demand is recurring, but platform innovation can change physician choices.

Business	Q3 2026 revenue	Organic growth	Business read-through
Endoscopy	$741M	−0.6%	China pricing and supply effects
Urology	$661M	−3.1%	Commercial execution and procedure challenges
Neuromodulation	$331M	+13.0%	Strong growth offset
MedSurg total	$1.733B	+0.7%	Diversified but slower
Cardiovascular total	$3.406B	+1.9%	Interventional Cardiology strength offset by EP/WATCHMAN

Business Takeaway

Boston Scientific's scale and physician relationships make its products durable, but the value of the franchise depends on retaining procedure share and healthy gross profit in the fastest-changing categories.

Industry, TAM & Market Share

Aging populations, minimally invasive treatment and better diagnosis expand procedures. Electrophysiology and left-atrial-appendage closure also attract well-financed competitors. Reimbursement changes and clinical evidence can alter adoption quickly. Addressable patient counts must be reduced for eligibility, access and physician willingness to change practice.

Market-Share Analysis

Comparable same-definition share data for the subject and its principal rivals were not established. TAM estimates and company-specific volume measures are not treated as directly comparable market shares. The positioning analysis below is more reliable than a table of unmatched percentages.

Competitive Scale / Position

Company / Platform	Primary Position	Relative Scale	Growth Direction	Investment Relevance
Medtronic (MDT)	Direct segments: electrophysiology, cardiac rhythm, neuromodulation	Product scope; no matched operating-scale series	Competes in overlapping procedures	Customer choice in the stated segment only
Abbott (ABT)	Direct segments: electrophysiology and structural heart	Product scope; no matched operating-scale series	Competes for physician and hospital adoption	Customer choice in the stated segment only
Johnson & Johnson — Biosense Webster	Direct segment: electrophysiology mapping and ablation	Product scope; no matched operating-scale series	EP procedure choice determines overlap	Customer choice in the stated segment only

Industry Takeaway

Addressable patient counts must be reduced for eligibility, access and physician willingness to change practice. The base case requires evidence of profitable adoption within that market.

Customer Economics

Training, clinical evidence and hospital relationships make recurring procedure demand relatively durable. Relevant measures are procedure growth, selling price, device utilization and incremental gross profit, rather than SaaS retention. A growing installed physician base helps only if products maintain outcomes and reimbursement support.

Customer-Economics Takeaway

The economic test is Cost savings, cash conversion and leverage. A growing installed physician base helps only if products maintain outcomes and reimbursement support.

Competitive Landscape & Moat

Competitive Landscape

The comparison is by procedure and device category. Orthopedic exposure alone does not make Stryker a broad Boston Scientific peer.

Competitor	Market Share	Positioning	Advantages vs. Company	Disadvantages vs. Company	Current Direction
Medtronic (MDT)	No consistent comparable series	Direct segments: electrophysiology, cardiac rhythm, neuromodulation	Broad clinical distribution and installed devices	Product-level outcomes matter more than group scale	Competes in overlapping procedures
Abbott (ABT)	No consistent comparable series	Direct segments: electrophysiology and structural heart	Competing mapping, ablation and Amulet offerings	Diagnostics and nutrition are outside the BSX comparison	Competes for physician and hospital adoption
Johnson & Johnson — Biosense Webster	No consistent comparable series	Direct segment: electrophysiology mapping and ablation	Established EP mapping/workflow ecosystem	Does not replicate every BSX cardiovascular franchise	EP procedure choice determines overlap

Moat Assessment

Regulatory approvals, clinical data, physician familiarity and broad distribution form a strong moat. Competitive product launches can still shift share. The latest slowdown argues for a stable-to-challenged near-term moat assessment in affected franchises rather than extrapolating historical share gains indefinitely.

Moat direction: Weakening — an analytical judgment about product and distribution economics, not a measured market-share claim.

Competitive Takeaway

Regulatory approvals, clinical data, physician familiarity and broad distribution form a strong moat. The direct rivals determine commercial pressure; diversified or sector anchors provide valuation context and are not substitutes for direct competition.

Financial Profile

Historical Financials

Financial reporting periods follow the issuer's fiscal year: completed FY rows plus standalone current-year quarters and cumulative H1/9M for FY2026. Revenue, FCF and SBC are flows; cash is a period-end balance. FCF = operating cash flow minus property/equipment capex from SEC company facts; quarterly FCF after Q1 and any quarterly SBC derived from YTD are visibly marked. Missing values are N/D, not zero. Unit: USD millions. Data extracted from SEC-tagged filings as of 2026-11-07. Company-specific FCF definitions and acquisition effects may require further reconciliation.

Period	Revenue	Growth	Gross Margin	Operating Margin	FCF	FCF Margin	SBC	Diluted Shares	Cash	Debt
FY2023	14,240	12.29%	69.16%	16.97%	1,792	12.58%	233	1,464	865	9,568
FY2024	16,747	17.61%	68.41%	17.93%	2,645	15.79%	266	1,486	414	11,228
FY2025	20,074	19.87%	68.78%	19.78%	3,658	18.22%	299	1,495	1,965	11,972
Q1 FY2026	$5,203	N/D	69.5%	21.2%	$171 (derived: CFO - capex)	3.3%	$83	1,495	$1,453	N/D
Q2 FY2026	$5,442	N/D	70.7%	21.6%	$1,279 (derived: current YTD - prior YTD)	23.5%	$87 (derived: current YTD - prior YTD)	1,474.8	$539	N/D
H1 FY2026	$10,646	N/D	70.1%	21.4%	$1,450 (derived: CFO - capex)	13.6%	$170	1,484.9	$539	N/D
Q3 FY2026	$5,138	N/D	66.7%	16.1%	$868 (derived: current YTD - prior YTD)	16.9%	$72 (derived: current YTD - prior YTD)	1,452	$609	N/D
9M FY2026	$15,784	N/D	69.0%	19.7%	$2,318 (derived: CFO - capex)	14.7%	$242	1,473.9	$609	N/D

Supplemental historical reporting context (retained)

Supplemental historical reporting context (retained)

Supplemental historical reporting context (retained)

Quarterly FCF derivation: Q1 = $348M CFO − $177M capex = $171M; Q2 = ($1,822M − $348M) CFO − ($372M − $177M) capex = $1,279M; Q3 = ($2,870M − $1,822M) CFO − ($552M − $372M) capex = $868M. Quarterly SBC: Q1 $83M, Q2 $170M − $83M = $87M, Q3 $242M − $170M = $72M. Corresponding Q3 SBC/FCF is approximately 8.3% and 9M SBC/FCF approximately 10.4%; FolioFacts derives ratios from matching periods rather than accepting a separate stored field.

Financial Takeaways

Q3 revenue was $5.138B, up 1.5%; GAAP diluted EPS $0.40 versus $0.51 and adjusted EPS $0.73 versus $0.75, below management's $0.80–$0.82 guidance. Adjusted gross margin fell to 68.0% from 71.0%; adjusted operating margin fell to 26.5% from 28.0%. Cyber costs caused material factory absorption and shipping headwinds, but worsening EP mix, WATCHMAN demand and China pricing create structural risks.

The company estimates the August cyber incident reduced Q3 revenue growth approximately 300 basis points and adjusted EPS $0.07, with another 200–300 basis points of Q4 revenue pressure as restocking unwinds. Management cut FY2026 organic growth guidance to ~3.75% and adjusted EPS to $3.16–$3.18; Q4 organic revenue is expected to decline 1–3%. Free cash flow remains positive, but 9M operating cash flow declined from $3.170B to $2.870B. September 30 cash totaled $609M against $11.953B debt. First-year Penumbra financing and share dilution remain uncertain.

Financial direction: Deteriorating in organic growth and margins; strong cash conversion persists.

Management & Capital Allocation

Management's past product commercialization is valuable, but repeated revisions to EP/WATCHMAN forecasts, a cybersecurity disruption and launch delays reduce near-term execution confidence. It plans more than $500M restructuring savings over three years, with more than half the savings on an exit-rate basis by the end of 2027; savings cannot alone recapture share. Penumbra's closing is expected in early 2027 after regulatory review. Previously guided $0.06–$0.08 first-year adjusted EPS dilution may rise with financing costs. The company completed an accelerated $2B repurchase, but new deal dilution and debt must be considered on a per-share basis.

Management Takeaway

Look for evidence that updated forecasting, product development, supply resilience and acquisition financing translate into stabilized U.S. EP sales, WATCHMAN referrals, improved margins and sustained per-share cash earnings.

Valuation

Current Valuation

Metric	Value
Price Snapshot	$42.75 — November 6, 2026 regular-session close
Shares Outstanding	~1.449B, October 29 2026 share count
Market Capitalization	$61.96B
Cash / Total Debt	$0.609B / $11.953B as of September 30, 2026
Enterprise Value	$73.31B
Trailing P/E	18.05×
Provider Forward P/E	13.87×
EV / Sales	~3.48× on latest-12-month revenue (not a cash-flow chart series)

Comparable Company Analysis

Company	Relevance	Public / Private	Forward P/E	EV / Sales	Growth / Margin / Risk Context
BSX — Boston Scientific	Subject company	Public	13.87×	3.48×	Cash-generative, challenged EP and WATCHMAN organic growth
MDT — Medtronic	Device competitor in specific cardiovascular/neuromodulation procedures; diversified valuation anchor	Public	16.95×	3.83×	Broader business mix; not a direct group-wide peer
ABT — Abbott	EP and LAAC segments; diversified valuation anchor	Public	18.84×	N/D	Diagnostics/diabetes complicate consolidated comparison
JNJ — Biosense Webster	Direct EP ablation and mapping product competitor	Listed parent	N/D	N/D	No matched product-level multiple; not a comparable consolidated P/E

Comparable takeaway: Same-provider November 6 quote convention for listed valuation anchors. The 18× BSX base exit multiple is an independent judgment about future normalized earnings rather than a mechanical peer average.

Valuation Scenarios

Scenario	Key Assumptions	Fair Value	Probability	Probability Rationale	Return From Price Snapshot
Bear	Sustainable 2029 EPS $2.75; exit P/E 13×; 12% discount over three years; prolonged franchise loss	$25.45	35%	Higher probability of persistent competition, financing drag and slow growth	−40.5%
Base	Sustainable 2029 EPS $3.85; exit P/E 18×; 12% discount over three years; weak 2027 then recovery	$49.33	50%	Diversified cash flows and eventual pipeline commercialization	+15.4%
Bull	Sustainable 2029 EPS $4.75; exit P/E 23×; 12% discount over three years; strong pipeline and deal execution	$77.76	15%	Multiple product recoveries and improved margins required	+81.9%
Probability-Weighted	35% × $25.45 + 50% × $49.33 + 15% × $77.76	$45.23	100%	Independent scenario weights	+5.8%

Valuation Takeaway

• Primary valuation method: Present value of sustainable 2029 EPS times exit P/E, discounted at 12% over three years. The EPS estimates are after recurring compensation, potential Penumbra financing and share dilution, not a naive extrapolation of adjusted EPS.
• Valuation refresh date / changes vs. previous: 2026-11-07. Bear/Base/Bull changed from $27.90/$58.37/$88.97 to $25.45/$49.33/$77.76; probabilities from 25/50/25 to 35/50/15, yielding P/W $45.23 versus $58.40 (−22.5%). Base sustainable EPS decreased from $4.10 to $3.85 and exit P/E from 20× to 18×; bear and bull multiples reduced to 13× and 23×. The 12% discount rate and three-year horizon are retained after reassessment to preserve consistent treatment of uncertain 2029 earnings. These are analyst assumptions, not issuer guidance or consensus.
• Cross-check methods: The issuer's 2026 adjusted EPS midpoint $3.17, positive cash flow, current quoted forward P/E 13.87× and similar-date MDT/ABT valuations. The base $3.85 sustainable EPS requires approximately 10% annual EPS growth in 2028 and 2029 after a difficult 2027.
• Key valuation dependencies: U.S. EP share stabilization, WATCHMAN referrals, China pricing, margins after cyber, the product timetable, Penumbra financing and dilution.
• Valuation confidence / Risk Level: 45/100 / Medium-High (previously 55/100).
• Margin-of-safety conclusion: Hold at the November 6 $42.75 reference price, with only +5.8% probability-weighted upside and −40.5% bear downside. Indicative research-date zone boundaries are Strong Buy ≤ $27.99, Buy up to $36.19, and Avoid Chasing above $50.26. FolioFacts alone calculates live zones, Opportunity Score and rank.

Analyst Questions

Full material Q3 2026 earnings-call Q&A, October 28. Questions and responses are original paraphrases rather than a transcript reproduction. Previous Q2 coverage remains in Git history.

Analyst / Firm	Core Question	Management Response	Research Read-Through
Robbie Marcus / JPMorgan	How much of the weak quarter and the difficult 2027 outlook is attributable to the cybersecurity disruption, and how much reflects underlying market weakness?	CFO Jon Monson estimated a $150 million sales hit and $0.07 EPS hit in Q3. Customer restocking after systems returned should produce another two to three points of revenue pressure and $0.04–$0.05 of EPS pressure in Q4. CEO Mike Mahoney said the larger 2027 issue is continued WATCHMAN market weakness and EP share erosion, even if the cyber effects fade.	The outage does not explain the whole reduction in forward earnings power.
Larry Biegelsen / Wells Fargo	Why should sales and earnings accelerate in 2028 despite delayed FARAFLEX development and possible new PFA competition?	Mahoney expects interventional and vascular businesses, together with Penumbra, to grow strongly, with MedSurg closer to mid-single-digit market growth. A new cardiac-rhythm platform, additional EP imaging and ablation launches, and possible WATCHMAN label developments are expected to improve the slower franchises. FARAFLEX remains a 2029 opportunity.	The anticipated 2028 recovery depends on multiple introductions and several markets, not one guaranteed launch.
Joanne Wuensch / Citi	What internal changes can bridge earnings to 2028, and what remains before the Penumbra deal can close?	Management described staff and cost restructuring, simpler reporting lines, supply-chain work and back-office changes. It expects more than $500 million of savings over three years and more than half of the savings by the end of 2027 on an exit-rate basis. It also said regulatory discussion had extended Penumbra's anticipated closing into early 2027, without a definitive date.	Cost savings may protect earnings, but acquisition timing and underlying growth remain separate risks.
Rick Wise / Stifel	Why should MedSurg grow only in the mid-single digits, rather than return to its former 7%–8% growth rate?	Neuromodulation remains strong. Endoscopy faces Chinese pricing cuts until it laps them late in 2027. Urology has suffered from weak stone-product performance and commercial turnover following the Axonics integration. Recent product clearances and added field staff are expected to improve Urology in 2027, while broader MedSurg acceleration is more likely in 2028.	Even outside EP and WATCHMAN, there are execution issues to resolve.
Travis Steed / Bank of America	Do the repeated product delays signal a deeper problem with the pipeline, and what has management changed in its forecasting process?	The CFO acknowledged that management had struggled to forecast the changing EP and WATCHMAN business cycle and described expanded scenario modeling, outside data and process changes. Mahoney acknowledged delays of roughly six months on some large platforms, citing development and regulatory complexity and a reorganization intended to improve launch discipline.	Better forecasts must be demonstrated through results; a stronger process is not yet evidence of a better outcome.
Josh Jennings / TD Cowen	Is Boston Scientific's estimated 7% weighted-average market growth rate still credible, and how does management view the U.S. EP market?	Mahoney said the overall market-growth estimate remains around 7%, potentially reaching 7%–8% as new categories and Penumbra are added. He continues to see a healthy EP market even while Boston Scientific loses share. Management expects the company to grow below its weighted market rate in 2027 and move back toward it in 2028.	End-market demand and Boston Scientific's competitive performance must be modeled separately.
Marie Thibault / BTIG	Why wouldn't restructuring produce adjusted EPS growth in 2027, even if revenue is weak?	Monson said product mix is the biggest constraint. Lower EP and WATCHMAN sales, combined with more intense pricing pressure in China, are expected to weigh on gross margin. Continued investment in quality and development offsets part of the savings. The company expects EPS growth to remain difficult without a revenue recovery.	Savings are an offset to deterioration, not an independent basis for higher earnings.
Pito Chickering / Deutsche Bank	Why is THRIVE running behind schedule, and why is VITALYST focusing initially on cardiogenic shock rather than high-risk PCI?	Chief Medical Officer Ken Stein said THRIVE enrollment has been slower than hoped during integration of the SoniVie team. For VITALYST, management wants to first pursue cardiogenic shock, where it believes the clinical need and potential benefit are compelling, rather than lead with the more debated high-risk PCI application.	The development strategy may be sensible, but launch timing and clinical success remain uncertain.
Matthew O'Brien / Piper Sandler	Are the FARAWAVE Ultra and FARAFLEX delays due to technical problems, clinical enrollment or manufacturing, and what can be said about the Penumbra delay?	Joe Fitzgerald attributed Ultra's roughly one-quarter slip primarily to design verification and validation across hardware, software and catheter components, rather than a required clinical trial. FARAFLEX has faced regulatory study approvals and practical startup challenges; management expects enrollment to ramp. Mahoney did not add details beyond Penumbra's expected early-2027 close.	These are different bottlenecks, but together they push the commercial recovery further into the future.
Matt Taylor / Jefferies	How has Penumbra's expected growth and its first-year EPS dilution changed since the deal was announced?	Monson said Penumbra remains an attractive growth addition, but the original $0.06–$0.08 estimated first-year adjusted EPS dilution used earlier financing assumptions. Higher interest rates may increase that dilution, and management will give a fuller update after closing.	Acquisition-driven growth needs to be judged after financing costs and dilution, not simply by added revenue.

Analyst-Q&A Takeaway

The Q3 call made clear that the cyber incident is not the whole problem. Analysts pressed management on EP and WATCHMAN competition, the 2027 trough, restructuring and Penumbra deal dilution, clinical program delays and recovery timing. Management anticipates more improvement in 2028–2029 but acknowledges weak 2027 organic growth and several milestones still ahead. This shifts valuation probability toward the bear case and lowers the sustainable base-case EPS and exit multiple.

Thesis Monitoring

Driver	Current State	Positive Trigger / Catalyst	Negative Trigger / Falsifier	What It Changes
EP ablation	U.S. EP −8% in Q3, losing share	Stabilization, 2D ICE/Ultra launches on time	Persistent share loss through product upgrades	Moat, base-case growth
WATCHMAN	Global −6%; U.S. standalone procedures down high teens	Stronger referrals and implementation of supportive clinical evidence	Deeper market slowdown or competitor share gains	Organic growth, scenario probabilities
Cyber normalization	Estimated Q3 300bp growth hit, Q4 200–300bp inventory normalization	Manufacturing and shipping margins rebound	Recurring disruption or permanent loss of orders	Near-term margins
Pipeline and innovation	EP imaging/ablation launches targeted 2027–2029	Timely launch and physician adoption	Further timing slips or limited adoption	2029 earnings, P/E
Cash and Penumbra	$609M cash, $11.953B debt, acquisition pending	Adequate cash flow, acceptable dilution and closing	Higher financing cost or integration trouble	Financial score and confidence
China price / MedSurg	Competitive pricing and weaker Urology	Price pressure normalizes, new product-led recovery	Continued ASP erosion and missed growth	Gross margin and multiple

Quality & Opportunity Scorecards

Quality Score

Component	Score	Weight	Weighted Contribution	Evidence
Business durability and economics	86	25%	21.50	Procedure demand, physician relationships, cash-generative product franchises
Moat and competitive position	76	25%	19.00	EP share loss and WATCHMAN competition despite approvals and clinical base
Growth runway and durability	63	20%	12.60	Attractive markets, but projected weak 2027 growth
Financial quality and balance sheet	73	15%	10.95	Positive FCF offset by acquisition financing and lower margins
Management, governance and capital allocation	69	15%	10.35	Past execution offset by reduced guidance and delayed launches
Quality Score	74.4	100%	74.40	Price-independent assessment, previously 80.1

• Quality Tier: B
• Speculative override: None

Live opportunity calculations and ranks are owned by FolioFacts. Prior Opportunity Score and Rank history is preserved below, not updated as a live research field.

Opportunity Score (Historical November 3, 2026 Snapshot — Not Current)

This table preserves the previously approved November 3, 2026 price-only score as archival evidence, including the Quality Score, probability-weighted upside, downside, confidence and shared rank from that prior research period. It does not apply the November 7 fundamental assumptions. FolioFacts owns all current opportunity scores, trading zones and ranks.

Component	Raw Input	Normalized Score	Weight	Weighted Contribution
Quality	80.1	80.1	30%	24.0
Probability-weighted upside	+34.3%	100.0	35%	35.0
Bear-case downside	-35.9%	14.1	20%	2.8
Risk / valuation confidence	55	55.0	15%	8.3
Opportunity Score		70.1	100%	70.1

• Opportunity Rank (historical): #5 of 76 on the November 3, 2026 snapshot.
• Zone Status (historical): Buy.
• Score-change rationale (historical): Price-only November 3 refresh; this is not the current Q3 research assessment.

<!-- NORMALIZED_SCORECARD_END -->

Portfolio Context

• Tracking tier: Primary Watchlist
• Owned: Yes
• Tracking source of truth: my_watchlist.md
• Portfolio source of truth: portfolio/holdings.md
• Scoring independence: Ownership, account, shares, position size and cost basis do not change research, valuation, Quality, Opportunity, rank or zones.

Investment Decision History

Timestamp	Price	Rating	Zone Status	Buy Zone	Strong Buy Zone	Avoid Chasing Above	Base FV	P/W FV	P/W Return	Quality	Opportunity / Rank	Change / Rationale
2026-10-21 (America/New_York)	$45.58	Buy	Buy	>$30.69–$46.72	≤ $30.69	> $64.89	$58.37	$58.40	+28.1%	80.1	69.5 / #7	Initial missing-file analysis; common-universe ranking; independent scenario assumptions
2026-11-07 (Q3 fundamental refresh)	$42.75	Hold	Hold / Watch (research date)	>$27.99–$36.19	≤ $27.99	> $50.26	$49.33	$45.23	+5.8%	74.4	FolioFacts only	Approved Q3 earnings refresh; 35/50/15 scenarios and $45.23 P/W; confidence 45, deterioration in EP/WATCHMAN and 2027 outlook; previous history preserved

---

Material Sources

Source	Type	Date / Period	What It Supports
Boston Scientific Q3 2026 earnings release	Company IR	2026-10-28 / Q3 2026	Sales, margins, EPS, organic growth, guidance and franchise results
Q3 2026 investor highlights	Company presentation	Q3 2026	Segment metrics, clinical and commercial milestones
BSX Q3 2026 SEC Form 10-Q	SEC filing	Filed 2026-11-02	Financial statements, cash, debt, SBC, shares, cyber risk
BSX Q2 2026 SEC Form 10-Q	SEC filing	Q2/H1 2026	Interim cumulative cash flow, Q2 diluted shares and SBC
BSX Q1 2026 SEC Form 10-Q	SEC filing	Q1 2026	Quarter CFO, capex, SBC, revenue and balance sheet
Q3 2026 earnings-call transcript	Transcript	2026-10-28	Full material Q&A and forward-looking management commentary
SIMPLAAFY WATCHMAN trial	Clinical trial, JAMA	2026-11-02	Post-implant medication trial outcomes and limitations
BSX historical annual financials	Standardized financial data	FY2023–FY2025	Annual revenue, margins, share count
BSX annual cash flows	Standardized financial data	FY2023–FY2025	Annual operating FCF and SBC
BSX November 6 close	Market data	2026-11-06	Dated share price
BSX valuation statistics	Market data	2026-11-06 quote, checked 2026-11-07	Market cap, EV, P/E and EV/Sales
MDT valuation statistics	Comparable market data	2026-11-06 quote	Matched provider/price-date peer multiple
ABT valuation statistics	Comparable market data	2026-11-06 quote	Matched provider/price-date peer multiple
Boston Scientific announces results for second quarter 2026 - Jul 29, 2026	Company IR / earnings filing	Q2 2026	Latest operating results, guidance, products and financial supplement
BSX complete earnings-call transcript	Transcript	Q2 2026	Prepared remarks and all material Q&A exchanges
BSX regular-session historical price	Market data	2026-10-20 close	Common price used in returns, scores and zones
BSX historical income statement	Standardized financial statements	Latest reported period and two preceding fiscal years	Historical income statement; source-native currency and definitions
BSX historical balance sheet	Standardized financial statements	Latest reported period and two preceding fiscal years	Historical balance sheet; source-native currency and definitions
BSX historical cash flows	Standardized financial statements	Latest reported period and two preceding fiscal years	Historical cash flows; source-native currency and definitions
Medtronic plc statistics	Comparable-company market data	2026-10-20 regular close	Peer multiples and financial context; public quote basis
Abbott statistics	Comparable-company market data	2026-10-20 regular close	Peer multiples and financial context; public quote basis
SEC XBRL company facts — BSX	Regulatory filing (as tagged)	FY2026, through 2026-09-30	Current-year standalone-quarter and year-to-date source facts for FCF, SBC, revenue and other reported metrics